Intervention

Coenzyme Q10 (Ubiquinone / Ubiquinol)

Last updated 2026-05-30· 1 min read· Evidence: rct

Reviewed by the Ultimate Longevity Bible editorial team. Educational reference — not medical advice. See disclaimer.

RCT evidence— Q-SYMBIO heart-failure trial

What it is

CoQ10 (ubiquinone in oxidised form, ubiquinol in reduced) is an electron carrier in the mitochondrial inner membrane shuttling electrons from complex I/II to complex III. It also serves as a lipid-phase antioxidant.

Why supplementation matters

Endogenous CoQ10 synthesis falls with age, especially after 40.
Statins block HMG-CoA reductase — the rate-limiting enzyme for both cholesterol and CoQ10 synthesis — reducing tissue CoQ10 by ~20–40%.
CoQ10 deficiency may contribute to statin-associated muscle symptoms (debated; SAMSON trial suggests nocebo dominates).

Evidence

Heart failure: Q-SYMBIO (2014) showed 300 mg/day reduced major adverse cardiovascular events and mortality in moderate-severe HFrEF.
Statin myopathy: mixed results, but reasonable trial to run in symptomatic patients before changing statin.
Migraine: meta-analyses show modest preventive benefit.
Female fertility / ovarian reserve: emerging trials show improvements in oocyte quality.
Longevity / mortality: KiSel-10 (Sweden) reported reduced cardiovascular mortality with selenium + CoQ10 in elderly.

Form matters

Ubiquinol is the active form; in adults over ~40, the body’s ability to reduce ubiquinone to ubiquinol declines. Pay the premium for ubiquinol in older adults.

References

Mortensen, S. A. et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure (Q-SYMBIO). JACC Heart Fail. 2, 641–649 (2014).